UK-based Celsis has introduced a new Celsis Accel System, a rapid microbial screening system with mid-range test volumes for the pharmaceutical manufacturers.
Featuring the firm’s reagent technology, the system has been designed to help reduce the time required for quality control assessment of microbial contamination.
The Celsis Accel System for Pharma integrates data security, remote data access and comprehensive data analysis tools into a compact system for pharmaceutical manufacturing facilities with midrange testing volumes.
Celsis CEO Jay LeCoque said: "We saw the need for a smaller-scaled instrument platform that still provided the full system security, data analysis and reporting tools necessary for the pharmaceutical market.
"The Accel System for Pharma provides all the functionality of our high volume Advance II system but in a smaller throughput format."
Celsis’s Financial Impact Assessment (FIA) has projected that the five-year net present value (NPV) for the average manufacturing facility for a company amounts to more than $300,000.
The company has also expanded its kit configuration options for its Celsis AMPiScreen reagent technology to improve varying testing volumes and to optimise reagent utilization.